How to reconstitute peptides: the vial is not a recipe

Reconstitution means adding a specified liquid to a dry, usually lyophilized drug so it returns to solution. It sounds like making a drink from powder. It is closer to rebuilding the last stage of a pharmaceutical formulation: the liquid controls the final concentration, while the way it enters the vial can affect sterility and physical stability.

That is why there is no responsible universal instruction that begins “add this much bacteriostatic water to any peptide.” A vial label has to answer four questions first: what molecule and formulation is this, what diluent is specified, what final concentration will result, and how long is that exact solution stable? If the vial, pharmacy label, and instructions do not answer them consistently, stop there. Do not use online arithmetic to repair missing product information.

Water makes injection possible, but it also gives molecules room to move, react, unfold, adsorb to surfaces, and associate with one another. Removing water by freeze-drying can slow many of those processes and extend shelf life. Reconstitution starts the solution-state clock again.

Peptides are not one stability class. Sequence, concentration, pH, salts, excipients, temperature, interfaces, and agitation can all change the risk of aggregation. A review of therapeutic-peptide stability documents all of those variables and includes familiar molecules—GLP-1, glucagon, amylin, insulin, calcitonin—as examples of peptides that can aggregate under particular conditions (Zapadka et al., 2017 · PMID 29147559). The point is not that every shake destroys every peptide. It is that formulation-specific evidence, not folklore, determines handling.

Sterile Water for Injection is sterile water without an antimicrobial preservative. Bacteriostatic Water for Injectioncontains a preservative, commonly benzyl alcohol, and is packaged for repeated withdrawals under its labeling. A preservative can limit some bacterial growth; it does not sterilize a contaminated vial, protect against viruses, or make poor technique safe.

The clearest proof that the two are not interchangeable comes from the same molecule. The FDA label for one tesamorelin formulation, EGRIFTA SV, specifies supplied Sterile Water, gentle rolling, immediate use, and disposal of the remainder (EGRIFTA SV prescribing information). A different tesamorelin formulation, EGRIFTA WR, specifies supplied Bacteriostatic Water, swirling, and use of the reconstituted vial for seven days at room temperature (EGRIFTA WR prescribing information). Same active peptide; different excipients, strengths, diluents, concentrations, handling, and storage. The label explicitly says the two formulations are not substitutable.

This is the general safety sequence—not a substitute for the product’s Instructions for Use and not a dosing protocol.

• Verify before opening. Match the drug name, formulation, vial strength, prescribed directions, supplied diluent, expiration date, and storage condition. Do not proceed if the seal is damaged, the label is incomplete, or the identities do not match.
• Set up a clean field. Wash and dry hands. Use a clean, dry preparation surface away from sinks, food, used sharps, and other contamination sources. Gather the exact diluent, new sterile syringe and needle, alcohol swabs, and a sharps container before starting.
• Use aseptic technique. Disinfect the vial stoppers and let them dry. Do not touch the stopper after cleaning, the needle, or any sterile connection. Use a new sterile needle and syringe for every vial access unless the product's own single-procedure instructions explicitly direct otherwise.
• Transfer the labeled volume. Draw and add only the volume specified for that exact vial. Direct the liquid as the product instructions show; do not improvise pressure, venting, or needle changes.
• Mix exactly as directed. Roll, swirl, or gently agitate only as the label instructs. Do not assume that shaking is acceptable—or that it is forbidden—without checking the product-specific directions.
• Inspect the result. Use only if its appearance matches the label. For a solution expected to be clear and colorless, do not use it if it remains cloudy, discolored, foamy beyond the stated settling time, or contains particles.
• Label the clock. Write the date and time of reconstitution and the product-specific discard date. Store it exactly as directed; refrigeration is not a universal answer.
• Dispose safely. Put used needles and syringes directly into an appropriate sharps container. Never leave a needle parked through the stopper between uses.

CDC’s injection-safety guidance makes the sterility logic explicit: prepare medication in a designated clean area, use aseptic technique, use a new sterile needle and syringe, prepare as close as possible to administration, and discard a vial whenever sterility is compromised or questionable (CDC injection-safety guidance). Those are minimum controls, not evidence that an unknown powder is fit for injection.

Reconstitution does not change the nominal mass printed on the vial. It changes how densely that mass is distributed through liquid. The governing relationship is simple:

If the same nominal vial is mixed with less liquid, each milliliter is more concentrated; with more liquid, each milliliter is less concentrated. That does not mean either choice is acceptable. The specified volume also has to satisfy the product’s compatibility, solubility, measurement, and stability requirements.

This is where “units” becomes dangerous language. Marks on an insulin syringe are volume graduations, not milligrams of every drug. The drug mass represented by a mark depends on the final concentration and the syringe calibration. FDA reports that patients using compounded semaglutide have drawn five to twenty times the intended amount, while some clinicians made five- to ten-fold errors converting among milligrams, milliliters, and syringe units (FDA dosing-error alert). A pharmacist should confirm the concentration and demonstrate the exact prescribed volume on the exact syringe being supplied.

Internet charts often assign every reconstituted peptide the same cold storage and discard window. Approved labels show why that cannot work. EGRIFTA SV says to use immediately and specifically says not to refrigerate the mixed solution. EGRIFTA WR permits seven days at controlled room temperature. A glucagon emergency kit directs use immediately after mixing and disposal of any unused portion (DailyMed glucagon label).

A generic 28-day number is also commonly misapplied. CDC cites 28 days as the usual maximum after first puncture for a manufacturer-labeled multidose vial, unless its manufacturer specifies another period. It does not grant every home-reconstituted vial 28 days of chemical stability or sterility. The finished drug’s labeled period can be much shorter.

A clear solution answers one narrow question: there is no obvious cloudiness, discoloration, or visible particulate matter under the conditions in which you looked. It does not prove identity, labeled mass, purity, potency, sterility, endotoxin control, or correct concentration. Microbial contamination can be invisible. So can a decimal-point error.

That distinction matters most for products sold as “research use only” or “not for human consumption.” FDA says unapproved GLP-1 products do not undergo its premarket review for safety, effectiveness, or quality and warns consumers not to purchase products falsely sold under research labeling for human use (FDA concerns with unapproved GLP-1 drugs). Adding sterile diluent to an unverified powder does not convert it into a sterile, approved, or pharmacy-dispensed medicine.